Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Lung Neoplasms 13Colorectal Neoplasms 11Neoplasms 8Mesothelioma, Malignant 7Mesothelioma 7Meningeal Carcinomatosis 7Neoplasm Metastasis 6Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Stomach Neoplasms 3Pancreatic Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2NSCLC 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Solid Tumor 2Urologic Neoplasms 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1

Interventions

Cisplatin 2tislelizumab 1pembrolizumab 1enfortumab vedotin 1cabozantinib 1VMBP protocol 1Pemetrexed 1Nivolumab 1Neoadjuvant Therapy 1Gemcitabine 1Docetaxel 1Carboplatin 1Administration, Intravesical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urologic Neoplasms × Pemetrexed × Clear all
NCT00374868 2010-11-04

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

Eli Lilly and Company

Phase 1/2 Completed
59 enrolled 17 charts
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡